K042455

16.0 510(k) Summary

Submitter's Name:

Sunrise Medical HHG, Inc.

Respiratory Products Division

100 DeVilbiss Drive Somerset PA 15501

Contact Person:

Allan Jones

Phone: 814-443-7618

Fax: 814-443-7571

Email: allan.jones@sunmed.com

Date Prepared:

September 1, 2004

Device Name:

Nasal CPAP Mask

Common or Usual Name:

Nasal CPAP Mask

DeVilbiss Model Number:

Model 9354 Series

Trade Proprietary Name:

DeVilbiss Nasal CPAP Mask

Established Registration

Number:

2515872

Classification Panel:

Anesthesiology

FDA Classification:

Class II

CFR Section:

868.5905 - Noncontinuous Ventilator (IPPB)

Product Code:

BZD

Legally Marketed Predicate Devices:

Device Name

510(k) Notification

Respironics Gel Mask Invacare Twilight Nasal Mask K954207 K022642

Description of Device:

The new DeVilbiss Nasal CPAP Mask serves as a mechanism for reliably connecting an adult (>30kg) patient diagnosed with sleep apnea to a source of continuous or bilevel positive air pressure needed to maintain an open airway. The nasal mask is securely fastened over a patient's nose by use of specialized headgear. A soft contact area is provided on the side of the mask that contacts the patient's face; the front side of the mask assembly has a tubing connection which is compatible with the industry standard 22mm air tubing.

The CPAP mask is required to be secure fitting to insure proper pressure delivery to the patient, but comfortable enough to maintain patient compliance with the treatment.

Air is supplied to the mask by a CPAP device (the CPAP device can be a standard CPAP, AutoAdjust CPAP or Bi-Level type device). Air is channeled to the nose chamber via the tubing/swivel adapter connections. The patient inhales air from the mask and exhales into the mask where continuous airflow from the CPAP device purges the exhaled carbon dioxide from the mask through the mask diffusion based exhaust holes. The mask will be held in place on the patient through the use of a cloth/elastic headgear.

Statement of Intended Use:

The new Nasal CPAP Mask is intended to be used with nasal continuous positive airway pressure (CPAP), auto-adjusting CPAP and Bilevel systems for the treatment of adult (>30kg) Obstructive Sleep Apnea (OSA). The device is to be used in home and clinical environments by or on order of a physician. The device can be used with auto-adjusting PAP devices which depend on patient flow signals or flow-based snoring signals for the determination of pressure adjustment.

Statement of Safety and Effectiveness:

The new Nasal CPAP Mask is equivalent in both function and indications for use to the Respironics Gel Mask (K954207) and Invacare Twilight Nasal Mask (K022642) legally marketed predicate devices.

The new Nasal CPAP Mask is designed for use on the order of a physician for the treatment of adult (>30kg) Obstructive Sleep Apnea. The mask is constructed of materials that are similar or identical to legally marketed devices. The unit is designed and manufactured to comply with voluntary standards applicable to this type of device.

The new Nasal CPAP Mask is designed to serve as a mechanism for reliably connecting an adult (>30kg) patient to a source of continuous or bilevel positive air pressure needed to maintain an open airway. The method of serving as the mechanism of connection to a continuous or Bilevel positive air pressure and other characteristics of the new Nasal CPAP Mask are substantially equivalent to other legally marketed devices.

Technological Characteristics:

The new Nasal CPAP Mask is strapped to the patient's face covering the nose, and connected via 22mm tubing to a source of continuous or Bilevel positive air pressure, creating an airway splint in the throat. Positive pressure ventilation is thus applied to the lungs in a non-invasavive way. The new Nasal CPAP Mask is equivalent in functional characteristics to the existing legally marketed predicate devices. The devices all function in providing a reliable mechanism of connection to a continuous, auto adjust or Bilevel positive air pressure source for the treatment of Obstructive Sleep Apnea. No new technologies have been introduced in the new Nasal CPAP Mask device.



JAN 1 4 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Allan Jones Manager, Sleep Products Engineering Sunrise Medical 100 DeVilbiss Drive Somerset, Pennsylvania 15501-2125

Re: K042455

Trade/Device Name: DeVilbiss Nasal CPAP Mask, Model 9354 Series

Regulation Number: 21 CFR 868.5905

Regulation Name: Noncontinuous Ventilator (IPPB)

Regulatory Class: II Product Code: BZD

Dated: November 24, 2004 Received: November 29, 2004

Dear Mr. Jones:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Indications for Use

510(k) Number (if known): K042455

Device Name: <u>DeVilbiss 9354 Series Nasal CPAP Mask</u>
Indications For Use:
The new Nasal CPAP Mask is intended to be used with nasal continuous positive airway pressure (CPAP), auto-adjusting CPAP and Bilevel systems for the treatment of adult (> 30Kg) Obstructive Sleep Apnea (OSA). The device is to be used in home and clinical environments by or on order of a physician. The device can be used with auto-adjusting PAP devices which depend on patient flow signals or flow-based snoring signals for the determination of pressure adjustment.
Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Anesthesiology, General Hospital, firstian Control, Dental Devices Page 1 of
510(k) Number Ko42455